News

EIT Launches call for STEM education initiatives

Published on | 2 months ago

Programmes
EIT

The EIT Higher Education Initiative's new call is designed to strengthen the innovation capacity and entrepreneurship within the STEM fields. By 2028, the initiative aims to impact 200,000 students, academics, and non-academic staff through training in innovation, entrepreneurship, and intellectual property management. A total budget of €70 million is allocated for this call, allowing up to €2 million per project over a 24-month period from 2026 to 2028.

The application deadline is set for 4 March 2026 at 17:00 CET. The first information sessions is scheduled for 15 December 2025 to offer further guidance on project priorities and collaboration opportunities. More details about the call can be found on the EIT website.

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1810 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.